Author's response to reviews

Title: The use of everolimus to target carcinogenic pathways in a patient with renal cell carcinoma and tuberous sclerosis complex: a case report

Authors:

Hye Sook Kim (hyesokim@gmail.com)
Seung Tae Kim (shty1@daum.net)
Seok Ho Kang (mdksh@korea.ac.kr)
Deuk Jae Sung (urorad@korea.ac.kr)
Chul Hwan Kim (chkap@korea.ac.kr)
Sang Won Shin (shinsw@kumc.or.kr)
Yeul Hong Kim (yhk0215@korea.ac.kr)
Won Yong Cho (wonyong@korea.ac.kr)
Kyong Hwa Park (khpark@korea.ac.kr)

Version: 3 Date: 29 October 2013

Author's response to reviews: see over
Dr. Michael Kidd  
Editor-in-Chief of *Journal of Medical Case Reports*

Re: Journal of Medical Case Reports MS: 1596147005954577  
The use of everolimus to target carcinogenic pathways in a patient with renal cell carcinoma and tuberous sclerosis complex: a case report

Thank you very much for your Decision Letter. The authors would also like to thank to the reviewers for their time and their valuable comments. We were pleased to know that our manuscript was rated as potentially acceptable for the publication in *Journal of Medical Case Reports*, subject to adequate revision and response to comments raised by the reviewers.

Please find attached a revised version of our manuscript “The use of everolimus to target carcinogenic pathways in a patient with renal cell carcinoma and tuberous sclerosis complex: a case report”, which we would like to resubmit for publication as a “Case report” in *Journal of Medical Case Reports*.

Your comments and those of the reviewers were highly insightful and enabled us to greatly improve the quality of our manuscript. In the following pages are our point-by-point responses to each of the comments of the reviewers as well as your own comments. Revisions in the text are shown using yellow highlight and bold characters for additions, and strikethrough font for deletions. In accordance with reviewer’s suggestion, we made several changes according to suggestions.

We hope that the revisions in the manuscript and our accompanying responses will be sufficient to make our manuscript suitable for publication in PLOS one. We shall look
forward to hearing from you at your earliest convenience.

Sincerely yours,

Kyong Hwa Park MD, PhD  
Division of Oncology/Hematology  
Department of Internal medicine  
Korea University College of Medicine  
73 Inchon-Ro, Sungbuk-gu, Seoul, Korea  
Tel: +82-2-920-6841; FAX: +82-2-920-6520; E-mail: khpark@korea.ac.kr
Author’s response to the reviewers’ comments

Manuscript number 1596147005954577

Title: The use of everolimus to target carcinogenic pathways in a patient with renal cell carcinoma and tuberous sclerosis complex: a case report

I am very much thankful to the reviewers for their deep and thorough review. I have revised my present research paper in the light of their useful suggestions and comments. I hope my revision has improved the paper to a level of their satisfaction. Number wise answers to their specific comments/suggestions/queries are as follows.

1. Summary of response to the reviewers’ comments and corrections/additions

Response to Reviewer #1 Comments

Again, we would like to express our appreciation for your extremely thoughtful suggestions. As you will see below we have been able to revise and improve the paper as a result of your valuable feedback.

Comments to authors:
Interesting report with strong biological rationale for therapy choice. Recommend having an English speaking reviewer carefully read and edit the report for grammar and style.

Thank you for your kind direction about our paper. We sent our manuscript to the English speaking reviewer, and had the reviewer edit our manuscript. As a result, there had come to many changes in words or phrases.

2. Answer to the associate editor’s report

Thank you very much for your kind words about our paper. We changed some words regarding the descriptions of the patients as you recommended.

1. Please change the description of the patient’s gender from woman to female.

: We changed the description from woman to female

2. Please include the Ethnicity of the patient in the Case presentation sections.

: We added “Korean” ethnicity in the sentence as shown below

In May 2009, a 49-year-old Korean female patient presented at our department with complaints of fever and left flank pain.
CLOSING COMMENTS TO THE EDITOR:

Again, we appreciate the opportunity to revise our work for consideration for publication in PLOS one. We hope our revision meet your approval. We next detail our responses to each reviewer’s concerns and comments.